Impact ledger
DexCom, Inc. (DXCM): the developments shaping its investment case
Follow the evidence affecting DexCom, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research DexCom, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-01
MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidance
Channel: Competitive dynamics and market share in the continuous glucose monitoring (CGM) market. Strong performance by a competitor could indicate a growing market but also increased competition.
mixed· 1-3m
2026-09-23
Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
Channel: Increased adoption of GLP-1/GIP drugs for type 2 diabetes and obesity may lead to a larger population requiring continuous glucose monitoring (CGM) for better disease management and monitoring of treatment efficacy.
Bullish· 1-5y
2026-09-14
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Channel: second_order_competitive_landscape
watch· 3-12m
Event impact log
4 events mapped to DXCM since 2026-09-01. Evidence through 2026-09-23.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide | Increased adoption of GLP-1/GIP drugs for type 2 diabetes and obesity may lead to a larger population requiring continuous glucose monitoring (CGM) for better disease management and monitoring of treatment efficacy. | Bullish | 1-5y | 0.30 |
| 2026-09-14 | MiniMed Group, Inc. and Medtronic plc File Communication Regarding Business Combination | Increased competition or market share shifts in continuous glucose monitoring (CGM) and insulin delivery systems. | watch | 3-12m | 0.30 |
| 2026-09-14 | Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc. | second_order_competitive_landscape | watch | 3-12m | 0.30 |
| 2026-09-01 | MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidance | Competitive dynamics and market share in the continuous glucose monitoring (CGM) market. Strong performance by a competitor could indicate a growing market but also increased competition. | mixed | 1-3m | 0.40 |
Continue this research
Build your DexCom, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the DXCM entity page →